Richard Gonzalez, AbbVie CEO (Chris Kleponis via AP Images)
December 19, 2022 01:33 PM ESTUpdated 03:30 PM
Pharma
FDA+

Ab­b­Vie adds de­pres­sion in­di­ca­tion to Vray­lar's la­bel months af­ter Gon­za­lez touts $4B+ peak sales po­ten­tial

Nicole DeFeudis

Editor

Ab­b­Vie CEO Richard Gon­za­lez wants to bring Vray­lar to new heights. On Fri­day, reg­u­la­tors set the next phase of his plan in mo­tion.

The FDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Vac­cine biotechs say they’ve been told to stop next-gen Covid work un­der a Biden-era project

Re­cent FDA staff cuts to de­lay drug hear­ing de­ci­sion by months, agency tells Van­da

Drug­mak­ers stock­pile in­ven­to­ry in the US, seek­ing to get ahead of Trump tar­iffs

Re­gen­eron to boost its US man­u­fac­tur­ing through a $3B Fu­ji­film deal

Up­dat­ed: Roche’s $50B US in­vest­ment in­cludes pre­vi­ous build an­nounce­ments

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times